Dual role of triglyceride structures facilitates anti-tumor drug delivery: Both as a self-assembling module and a responsive module DOI

Wenxin Zhong,

Yalin Xu,

Zixuan Wang

et al.

Journal of Colloid and Interface Science, Journal Year: 2024, Volume and Issue: 678, P. 24 - 34

Published: Sept. 11, 2024

Language: Английский

Redox-manipulating nanocarriers for anticancer drug delivery: a systematic review DOI Creative Commons
Xuan Meng,

Yongli Shen,

Huanyu Zhao

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Sept. 28, 2024

Language: Английский

Citations

17

Carbon-Spaced Tandem-Disulfide Bond Bridge Design Addresses Limitations of Homodimer Prodrug Nanoassemblies: Enhancing Both Stability and Activatability DOI
Hao Zhang, Tian Liu,

Yitong Sun

et al.

Journal of the American Chemical Society, Journal Year: 2024, Volume and Issue: 146(32), P. 22675 - 22688

Published: Aug. 1, 2024

Redox-responsive homodimer prodrug nanoassemblies (RHPNs) have emerged as a significant technology for overcoming chemotherapeutical limitations due to their high drug-loading capacity, low excipient-associated toxicity, and straightforward preparation method. Previous studies indicated that α-position disulfide bond bridged RHPNs exhibited rapid drug release rates but unsatisfactory assembly stability. In contrast, γ-disulfide showed better stability rates. Therefore, designing chemical linkages ensure both stable remains challenging. To address this paradox of in RHPNs, we developed carbon-spaced double-disulfide (CSDD)-bridged (CSDD-RHPNs) with two carbon-spaces. Pilot CSDD-RHPNs carbon-spaces enhanced stability, reduction-responsive release, improved selective toxicity compared α-/γ-position single RHPNs. Based on these findings, four six were designed further investigate the properties CSDD-RHPNs. These excellent ability, safety, prolonged circulation. Particularly, displayed best antitumor efficacy 4T1 B16–F10 tumor-bearing mice. CSDD offer novel perspectives rational design potentially regarding contradictory ability rate.

Language: Английский

Citations

9

Carrier-Free Nanodrugs: From Bench to Bedside DOI

Fang Fang,

Xiaoyuan Chen

ACS Nano, Journal Year: 2024, Volume and Issue: 18(35), P. 23827 - 23841

Published: Aug. 20, 2024

Carrier-free nanodrugs with extraordinary active pharmaceutical ingredient (API) loading (even 100%), avoidable carrier-induced toxicity, and simple synthetic procedures are considered as one of the most promising candidates for disease theranostics. Substantial studies commercial success "carrier-free" nanocrystals have demonstrated their strong clinical potential. However, practical translations remain challenging impeded by unpredictable assembly processes, insufficient delivery efficiency, an unclear in vivo fate. In this Perspective, we systematically outline contemporary emerging carrier-free based on diverse APIs, well highlight opportunities challenges translation. Looking ahead, further improvements design preparation, drug delivery, efficacy, safety nanomedicines essential to facilitate translation from bench bedside.

Language: Английский

Citations

9

Nanotechnology for tau pathology in Alzheimer's disease DOI Creative Commons
Rongrong Ma,

Qianwen Mu,

Yue Xi

et al.

Materials Today Bio, Journal Year: 2024, Volume and Issue: 27, P. 101145 - 101145

Published: July 2, 2024

Tau protein aggregation is a defining characteristic of Alzheimer's disease (AD), leading to the formation neurofibrillary tangles that disrupt neural communication and ultimately result in cognitive decline. Nanotechnology presents novel strategies for both diagnosing treating disease. Nanotechnology. It has become revolutionary tool fight against disease, particularly addressing pathological accumulation tau protein. This review explores relationship between tau-related neurophysiology utilization nanotechnology AD treatment, focusing on application nanomaterials regulate phosphorylation, hinder propagation, stabilize microtubules, eliminate emphasize potential developing personalized therapies monitoring treatment responses patients. combines with provide new insights further understanding

Language: Английский

Citations

7

Intelligent responsive nanogels: New Horizons in cancer therapy DOI
Mazlina Musa, Xinxin Sun, Jianbin Shi

et al.

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 669, P. 125050 - 125050

Published: Dec. 5, 2024

Language: Английский

Citations

5

Rational engineering of cholesterol-modified prodrug nanoassemblies for improving the tumor selectivity and safety of mitoxantrone DOI Creative Commons
Bowen Zhang, Wenyuan Liu, Jinrui Liu

et al.

Fundamental Research, Journal Year: 2024, Volume and Issue: unknown

Published: June 1, 2024

Mitoxantrone (MTO) is an anthraquinone antitumor drug with potent therapeutic benefits. However, its clinical application restricted by the severe side effects stemming from poor tumor selectivity. In this study, MTO and cholesterol (CLS) were conjugated via a tumor-selective disulfide bond to obtain MTO-SS-CLS prodrug. Interestingly, could self-assemble into uniform nanoassemblies, addition of DSPE-PEG2K significantly improved self-assembly behavior stability. Moreover, compared solutions, bond-bridged nanoassemblies exhibited heightened selectivity pharmacokinetic properties. addition, prodrug tolerated dose safety without compromising effect. This research enriches pharmaceutical paves way for extensive application.

Language: Английский

Citations

4

Mitoxantrone‐Encapsulated ZIF‐8 Enhances Chemo‐Immunotherapy via Amplified Immunogenic Cell Death DOI Creative Commons
Junhong Li,

Wenxing Lv,

Ziwei Han

et al.

Advanced Science, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Abstract Chemo‐immunotherapy, combining systemic chemotherapeutic drugs and immune checkpoint blockers, is a promising paradigm in cancer treatment. However, challenges such as limited induction of responses toxicity have hindered its clinical applications. Here, zeolite imidazolate framework‐8 (ZIF‐8) that encapsulates mitoxantrone (MIT), an cell death (ICD)‐inducing agent (MIT@ZIF‐8), synthesized using one‐pot aqueous‐phase process. ZIF‐8 serves dual‐functional nanomaterial for chemo‐immunotherapy: carrier to enhance tumor uptake MIT improved chemotherapy efficacy, pyroptosis inducer amplify MIT‐induced ICD augmented anti‐tumor responses. As result, vivo administration MIT@ZIF‐8 markedly inhibits growth both immunologically “hot” colon “cold” prostate cancer. Moreover, treatment increases the abundance cytotoxic CD8 + T cells reduces amount immunosuppressive regulatory tumors, thereby enhancing immunity sensitizing anti‐CTLA‐4 immunotherapy. In summary, offers highly translational approach chemo‐immunotherapy.

Language: Английский

Citations

0

Long-acting bioengineered platelets with internal doxorubicin loaded and external quercetin liposomes anchored for post-surgical tumor therapy DOI
Qi Lu,

Zeyu Han,

Xia Wang

et al.

Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 381, P. 113546 - 113546

Published: Feb. 27, 2025

Language: Английский

Citations

0

ROS-related nanoparticles for the management of Alzheimer’s disease: Wielding the double-edged sword DOI

Yibin Yu,

Qi Zhang, Yihao Guo

et al.

Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 161784 - 161784

Published: March 1, 2025

Language: Английский

Citations

0

Carrier-free nano-prodrugs for enhanced cancer therapy: stimuli-responsive design and applications DOI
Yoshitaka Koseki

Polymer Journal, Journal Year: 2025, Volume and Issue: unknown

Published: April 11, 2025

Language: Английский

Citations

0